IL6 and atherosclerosis: In humans, a clinical trial (Bacchiega et al., 2017) proved that IL-6 is a major player in the inflammatory events leading to atherosclerosis and the blockade of this cytokine with specific inhibitors like tocilizumab may reduce cardiovascular risk, unfortunately with significant adverse reactions [90].